Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 24.7688
- Book/Share 29.2044
- PB 4.6102
- Debt/Equity 0.2657
- CurrentRatio 1.8207
- ROIC 0.188
- MktCap 233117080335.0
- FreeCF/Share 3.8927
- PFCF 34.4084
- PE 16.6762
- Debt/Assets 0.16
- DivYield 0.0173
- ROE 0.2993
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ABT | Jefferies | Hold | Buy | -- | $145 | July 18, 2025 |
| Initiation | ABT | Leerink Partners | -- | Market Perform | -- | $143 | June 16, 2025 |
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
Published: September 30, 2025 by: Proactive Investors
Sentiment: Positive
UBS analysts are ‘Overweight' the healthcare equipment sector, with a Number One ranking on their total scorecard. In a note to clients on Tuesday, the analysts wrote that healthcare equipment has had the highest growth rate historically, excluding technology, at a 9% compound annual growth rate (CAGR) and the sector's earnings per share are now trading 10% below trend.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
Read More
Abbott Hosts Conference Call for Third-Quarter Earnings
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.
Read More
1 Dividend King To Hold And 2 Worth Buying Now
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
It's often said that cash is king, but I would take it one step further. Abbott Laboratories is an AA-rated Dividend King with healthy growth prospects but a rich valuation. I'm waiting for a pullback to the low-$120 range before upgrading back to a buy. Federal Realty owns top-notch properties in demographically thriving markets, possesses a conservatively leveraged balance sheet, and has the longest track record of dividend growth in REITdom.
Read More
Abbott Declares 407th Consecutive Quarterly Dividend
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral
ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
Read More
Is it the Right Time to Retain Abbott Stock in Your Portfolio?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABT's strong Nutrition, Diabetes Care and EPD growth fuel momentum, but macro and currency headwinds challenge its outlook.
Read More
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Read More
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.
Read More
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, according to Grand View Research. Abbott Laboratories ABT and Edwards Lifesciences EW are two key players with significant presence in this sector.
Read More
Best Dividend Aristocrats For September 2025
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY in August.
Read More
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
Read More
NVST or ABT: Which Is the Better Value Stock Right Now?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Abbott Gains in Nutrition With Adult Segment Leading Growth
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
Read More
Abbott Taps Growing TMVR Market With Tendyne System
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Read More
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.
Read More
NVST vs. ABT: Which Stock Is the Better Value Option?
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
3 Dividend Growth Stocks That Will Deliver Meaty Returns After 5 Years
Published: July 28, 2025 by: 24/7 Wall Street
Sentiment: Positive
Sufficient earnings growth to continually increase dividends at a comfortably low payout ratio that also accommodates expansion capex is an excellent signal for strong upside potential.
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
NVST or ABT: Which Is the Better Value Stock Right Now?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Best Dividend Kings: July 2025
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
Read More
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
Published: July 18, 2025 by: MarketBeat
Sentiment: Positive
If you wonder whether Abbott Laboratories NYSE: ABT is a good buy in Q2 2025, the answer is yes. The company's management, portfolio, cash flow, capital return, and pipeline are why.
Read More
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Read More
Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
Published: July 18, 2025 by: Benzinga
Sentiment: Neutral
Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Robert B. Ford
- Employees 114000